4-Sep-2026
ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
PRNewswire (Thu, 3-Sep 7:15 AM ET)
ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
PRNewswire (Thu, 13-Aug 7:30 AM ET)
ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
PRNewswire (Thu, 6-Aug 7:30 AM ET)
ADC Therapeutics Announces New Employee Inducement Grant
PRNewswire (Wed, 1-Jul 4:05 PM ET)
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA Combination Trial
PRNewswire (Tue, 30-Jun 7:15 AM ET)
PRNewswire (Wed, 24-Jun 7:31 AM ET)
Globe Newswire (Tue, 23-Jun 5:50 PM ET)
Globe Newswire (Tue, 16-Jun 5:36 PM ET)
Market Chameleon (Wed, 4-Mar 6:20 AM ET)
ADCT Faces Investor Investigation Following Safety Concerns in Clinical Trial Data
Market Chameleon (Fri, 16-Jan 6:11 AM ET)
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Adc Therapeutics SA Common Shares trades on the NYSE stock market under the symbol ADCT.
As of September 4, 2026, ADCT stock price climbed to $1.36 with 1,433,106 million shares trading.
ADCT has a beta of 3.21, meaning it tends to be more sensitive to market movements. ADCT has a correlation of 0.08 to the broad based SPY ETF.
ADCT has a market cap of $173.63 million. This is considered a Micro Cap stock.
Last quarter Adc Therapeutics SA Common Shares reported $19 million in Revenue and -$.11 earnings per share. This beat revenue expectation by $101,200 and exceeded earnings estimates by $.10.
In the last 3 years, ADCT traded as high as $6.04 and as low as $.36.
The top ETF exchange traded funds that ADCT belongs to (by Net Assets): VTWO, IWO, GWX, VTWV, RSSL.
ADCT has underperformed the market in the last year with a return of -60.0%, while SPY returned +19.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ADCT shares. However, ADCT has outperformed the market in the last 3 month and 2 week periods, returning +3.0% and +36.5%, while SPY returned +2.0% and +0.6%, respectively. This indicates ADCT has been having a stronger performance recently.
ADCT support price is $1.25 and resistance is $1.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADCT shares will trade within this expected range on the day.